Successful Liver Transplantation in a Patient With Acute COVID-19 Infection and Acute Liver Failure: A Case Report

Kristen M. Kidson, MD, FRCPC,1,2 Jeieung Park, MD, FRCP,1 Marthe K. Charles, MD, MSc, FRCP,3,4 Mahmoud Omar, MD, MSc,5,6 Mel Krajden, MD, FRCP,4 Alissa J. Wright, MD, MSc, FRCP,7 Trana Hussaini, PharmD,8 Peter T. W. Kim, MD, MSc, FRCSC,9 Stephen W. Chung, MD, PhD, FRCP,9 and Eric M. Yoshida, MD, MHS, FRCPC10

Abstract: Current liver transplantation societies recommend recipients with active coronavirus disease 2019 (COVID-19) be deferred from transplantation for at least 2 weeks, have symptom resolution and at least 1 negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test.1 This approach does not address patients who require urgent transplantation and will otherwise die from liver failure. We report a successful orthotopic liver transplant (OLT) in a patient with active COVID-19 infection. This is only the second to be reported worldwide and the first in Canada.

CASE PRESENTATION

A 28-y-old male, previously healthy, was transferred to our institution for possible OLT. He presented 5 d earlier to a community hospital with new onset jaundice and acute liver failure (ALF) of unclear etiology. The history revealed a 1-y duration of heavy alcohol consumption. Work-up was negative for acetaminophen, viral, autoimmune, and infiltrative etiologies. Ultrasound done at the time of admission showed patent vasculature and no cirrhosis. Laboratory investigations completed during his hospitalization are outlined in Table 1. Our patient had 2 negative RT-PCR SARS-CoV-2 tests, 1 at the community hospital on day −22, and 1 the day a SARS-CoV-2 outbreak was reported on the ward to which the patient was admitted, day −14 (using the day of OLT as day 0, see Table 2). His first positive SARS-CoV-2 RT-PCR test occurred 5 d into his admission at our institution.

Three days later (day −9), he deteriorated, developing new onset hepatic encephalopathy and was intubated for altered level of consciousness. Computed tomography of the head did not reveal neuroradiologic findings consistent with COVID-19 or elevated intracranial pressure.2 COVID-19 infection appeared to be confined to the upper respiratory tract without fever or preceding cough. He was mechanically ventilated with a pressure support of 5 cm H2O, positive end-expiratory pressure of 5 cm H2O and FiO2 30%. Arterial blood gas on these settings showed a PaO2 of 122 mm Hg and Paco2 of 40 mm Hg. Treatment specific to COVID-19 infection was not initiated as our patient did not demonstrate pulmonary involvement or hypoxemia.3 Further hepatic decompensation occurred day −1 with refractory lactic acidosis, hypoglycemia, and hypothermia. Continuous renal replacement therapy was initiated for acute kidney injury and volume overload. His chest x-ray only demonstrated bilateral pleural effusions. Computed tomography of the abdomen revealed large areas of hepatic hypodensity, large volume ascites, but no evidence of thrombosis. His model for end-stage liver disease-sodium score was 47, and Child-Pugh score was 14.
The patient underwent a successful OLT 12 d after his initial positive SARS-CoV-2 RT-PCR test. At the time of transplant, he had active COVID-19 infection (Table 2). Intraoperatively, the patient did not demonstrate systemic effects of COVID-19. He required minimal ventilatory support and was hemodynamically stable, transesophageal echocardiography did not demonstrate evidence of ventricular dysfunction, and no evidence of hypercoagulability was noted on rotational thromboelastography.4,5 Pathology obtained from the explanted liver demonstrated confluent central perivenular and submassive hepatic necrosis, marked cholestasis, preserved portal tracts, and normal vascular structures.

The patient improved rapidly posttransplant. He was extubated day 1, and continuous renal replacement therapy was discontinued. Immunosuppression was induced with corticosteroids. Tacrolimus was initiated on day 1, and mycophenolate mofetil was initiated on day 6. Liver allograft function improved postoperatively (Table 1). Liver biopsy performed day 9 was normal. The patient was discharged on day 15 at which time he had evidence of early antibody response to SARS-CoV-2. Full antibody response was seen 2 wks later (Table 2). By day 53, our patient was no longer positive for SARS-CoV-2 using RT-PCR from a nasopharyngeal sample and had never demonstrated clinical evidence of COVID-19 relapse.

### Table 1. Laboratory test results relative to the time of orthotopic liver transplantation

| Test                          | Day −22 | Day −12 | Day −9 | Day −5 | Day −1 | Day4 | Day6 | Day 12* | Days 26–32 | Days 55–58 |
|------------------------------|---------|---------|--------|--------|--------|------|------|---------|------------|------------|
| WBC (× 10^9/L)               | 6.1     | 13.3    | 12.4   | 19     | 9      | 6.7  | 6.2  | 10      | 11         | 9.9        |
| Neutrophil count (× 10^9/L)  | 3.9     | 6.7     | 9.2    | 15.9   | 7.5    | –    | –    | –       | –          | –          |
| Lymphocyte count (× 10^9/L)  | 1.5     | 3.8     | 1.2    | 1.9    | 0.8    | –    | –    | –       | –          | 1.8        |
| Hemoglobin (g/L)             | 153     | 164     | 145    | 155    | 93     | 73   | 85   | 87      | 115        | 120        |
| Platelet count (× 10^9/L)    | 109     | 125     | 78     | 75     | 46     | 23   | 32   | 124     | 222        | 205        |
| Serum lactate (mmol/L)       | –       | 1.7     | 2.4    | 6.7*   | 5.3    | 1.4  | –    | –       | –          | –          |
| Serum sodium (mmol/L)        | 138     | 139     | 138    | 135    | 140    | 146  | 151* | 139     | 139        | 140        |
| Serum creatinine (µmol/L)    | 80      | 84      | 75     | 157    | 214    | 147  | 124  | 72      | 83         | 86         |
| INR                          | 2.2     | 2.7     | 4      | 4.1    | 3.3    | 0.9  | 1    | 1       | 0.9        | 1          |
| Total bilirubin (µmol/L)     | 280     | 408     | 419    | 252    | 378    | –    | 37   | 13      | 8          | 5          |
| Serum albumin (g/L)          | –       | 27      | 21     | 29     | 25     | 23   | 19   | 35      | 35         | 41         |
| Ammonia (µmol/L)             | –       | 85     | 184    | 106*   | 183*   | –    | –    | –       | –          | –          |
| AST (U/L)                    | 1816*   | 743     | 785    | 618    | 291    | 100  | 181  | 113     | 53         | 14         |
| ALT (U/L)                    | 2177    | 1470    | 1393   | 915    | 237    | 175  | 308  | 231     | 83         | 18         |
| ALP (U/L)                    | 196*    | 310     | 245    | 230    | 129    | 94   | 37   | 101     | 93         | 54         |
| GGT (U/L)                    | 254     | 293     | 195    | 128    | 26     | 114  | 173  | 159     | 72         | 24         |
| C-reactive protein (mg/L)    | 3.2*    | 4*      | 2.8    | 6.5    | –      | –    | –    | –       | –          | –          |
| D-dimer (µg/L)               | –       | 766*    | 1181   | 5632*  | –      | –    | –    | –       | –          | –          |
| LDH (U/L)                    | –       | 413     | 554    | 617    | 404    | 350  | 369  | 321     | –          | –          |
| Ferritin (µg/L)              | –       | –       | 10.259 | 5535*  | –      | –    | –    | –       | –          | –          |
| Procalcitonin (µg/L)         | –       | –       | 0.27   | –      | –      | –    | –    | –       | –          | –          |
| Tacrolimus level (µg/L)      | –       | –       | –      | 6.6    | 10.6   | 6.1  | 6.1  | 9.1     | –          | –          |

*If result was unavailable, a result within 36 h of that date was used.
*–* signifies no test result available.
ALP , alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, Gamma-glutamyl transferase; INR, international normalized ratio; LDH, lactate dehydrogenase; WBC, white blood cell count.

### Table 2. SARS-CoV-2 test results relative to time of orthotopic liver transplantation

| Date of test relative to the day of orthotopic liver transplant (day 0) | Day −22 | Day −14 | Day −12 | Day −3 | Day −2 | Day −1 | Day 6 | Day 12 | Days 26–32 | Days 55–58 |
|-----------------------------------------------------------------------|---------|---------|---------|--------|--------|--------|-------|--------|------------|------------|
| SARS-CoV-2 RT-PCR (NP)                                               | –       | –       | +       | +      | +      | +      | +     | +      | –          | –          |
| SARS-CoV-2 RT-PCR cycle threshold E gene (NP)*                       | 29.5    | 15.5    | 18.6    | 22.1   | 23.7*  | 27.5   | 29.3* | –      | –          | –          |
| SARS-CoV-2 RT-PCR cycle threshold RdRP gene (NP)*                    | 28.7    | 18.1    | 26.8    | –      | –      | –      | –     | –      | –          | –          |
| SARS-CoV-2 RNA (serum)                                               | +       | –       | –       | –      | –      | –      | –     | –      | –          | –          |
| COVID-19 total antibodya                                             | –       | –       | +       | +      | +      | +      | +     | –      | +          | –          |
| COVID-19 IgG antibodya                                               | –       | –       | +       | +      | +      | +      | –     | –      | –          | –          |

*Cycle threshold values are from laboratory-developed tests for E gene, or commercial test Panther Hologic Fusion* and Roche Coba†.
*Cycle threshold values are from laboratory-developed tests for RNA-dependent RNA polymerase gene.
Commercially available assay (Siemens Total Ab) detects IgA, IgM, and IgG antibodies against spike protein.
Commercially available assay (Abbott Architect) detects IgG against nucleocapsid protein.
+ Indicates a positive result. – Indicates a negative result.
COVID-19, coronavirus disease 2019; NP, nasopharyngeal swab; RdRP, RNA- dependent RNA polymerase; RT-PCR, reverse transcriptase-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
DISCUSSION

No reports of successful OLT in patients with active COVID-19 existed at the time of our decision to proceed with transplantation. Kulkarni et al demonstrated OLT in patients recently (but not acutely) infected with COVID-19. One case report suggested successful OLT during active COVID-19; however, the patient did not have evidence of active infection. We applaud the latest case, similar to ours, which highlights successful OLT in a patient with mild active COVID-19 infection. Although this case report was published after our patient was discharged from hospital, our case adds to existing literature.

Our patient had acute COVID-19 infection at the time of OLT as (a) he was previously RT-PCR negative, (b) RT-PCR cycle threshold was low, (c) no antibodies against SARS-CoV-2 were detectable, and (d) SARS-CoV-2 viral RNA (RNA) was detected in his serum. Viral load (VL) is often reported as cycle threshold (Ct), the time for the amplified viral signal to cross detection threshold; a lower Ct indicates higher VL. Detecting SARS-CoV-2 RNA in serum is common when the VL detected on nasopharyngeal swab is high. The absence of antibodies to SARS-CoV-2 provided further evidence of active COVID-19. Antibodies to SARS-CoV-2 form as early as 4 d from the onset of infection, with 50% and 90% of patients seroconverting at 7 d and 3 wks, respectively. Initial hepatic decompensation in this patient was not from COVID-19; his ALF and biochemical deterioration preceded COVID-19 infection. Although the initial cause of ALF remains unknown, the explanted liver suggested potential drug or toxin-induced injury. A secondary cause for further hepatic decompensation during the patient’s admission, however, was possible. Concern existed if decompensation was COVID-19 related, potential multisystem involvement may occur following transplantation. COVID-19 can cause liver injury, but it is typically mild with minimal impairment in synthetic function. We cannot rule out that COVID-19 infection did not contribute to further decompensation during hospital admission; however, imaging and pathology from the explanted liver did not demonstrate features consistent with COVID-19-related liver injury.

Following a multidisciplinary discussion, we proceeded with OLT based on the patient’s young age and mild COVID-19 disease, which appeared isolated to the upper respiratory tract. He had limited risk factors for adverse outcome from COVID-19 infection according to data extrapolated from the general population, operative patients or liver transplant recipients (LTR). In fact, LTR have lower mortality from COVID-19 than the general population and earlier time because transplant or immunosuppression does not correlate with worse outcome. We explored the association between VL, Ct from respiratory secretions or presence of serum SARS-CoV-2 RNA (RNA-emia), and disease severity in COVID-19. RNA-emia has a stronger association with mortality and disease severity than respiratory tract VL or Ct. However, RNA-emia and respiratory tract VL have only been shown to predict adverse outcome in patients with COVID-19 that require hospitalization. The presence of high VL and RNA-emia in our patient were of uncertain consequence given that his hospitalization was driven by ALF, not respiratory symptoms. Although low Ct values are associated with positive viral cultures, limitations to interpretation of VL in serum and respiratory secretions exist. Ct may be low due to high viral RNA load without viable virus, no consistent Ct cutoff exists, and variability in sample collection and reaction conditions may alter gene amplification. Finally, time from initial SARS-CoV-2 infection was considered. The infectious period of SARS-CoV-2 peaks at symptom onset and declines over 10 d in immunocompetent patients and 15 d in immunosuppressed patients. It is possible that the highly infectious period for our patient had passed at time of OLT; potentially reducing the chance of COVID-19 relapse during the postoperative period.

Although our patient exhibited active COVID-19 infection, it remained unclear what his outcome following OLT would be, but it was certain that without OLT, he would die. Waiting for 2 wks or a negative RT-PCR test was not feasible. Patients can have prolonged detection of viral RNA without isolated active virus; this does not predict mortality nor inform about immune response. Our patient exhibited prolonged RT-PCR positivity despite full antibody response. Allocation of a scarce organ resource in a patient with unknown outcome was also considered. Liver transplant centers across Canada were contacted as listing our patient as “high status” would result in our patient receiving the next available organ. All transplant centers were agreeable, and none reported encountering a similar case.

Before OLT, we considered treatment of COVID-19. We elected against using corticosteroids or tocilizumab, as benefits are only seen in patients requiring supplemental oxygen. Our patient was intubated for airway protection, not hypoxemia. Yohanathan et al used remdesivir in their SARS-CoV-2 positive OLT recipient, whereas we believed no evidence for its use in our patient existed, and it could cause transaminis. Convalescent plasma was not given due to lack of benefit in COVID-19, despite it being used by others. Immunosuppression may attenuate the immune response to COVID-19. Tacrolimus improves survival in LTR with COVID-19 without increasing the risk of severe COVID-19. Conversely, mycophenolate mofetil (MMF) may increase the risk of severe COVID-19 in a dose-dependent manner. Holding antimetabolite immunosuppressive agents have not been shown to increase risk of organ rejection. With this evidence, we initiated tacrolimus immediately postoperatively, while MMF introduction was delayed to avoid initial over immunosuppression. A renal-sparing immunosuppression protocol was considered. Given that most patients with acute kidney injury in the setting of ALF have renal recovery after OLT, along with the beneficial effect of tacrolimus in COVID-19, we proceeded with early tacrolimus initiation. Posttransplant biopsy confirmed this strategy of immunosuppression, similar to others, to be effective.

This case highlights challenges in risk stratification of patients awaiting OLT who become SARS-CoV-2 positive. Lack of data on long-term effect of COVID-19 in transplant recipients and effect of immunosuppression makes the decision difficult. Although the ethical concerns of allocating a scarce organ resource to a patient with unknown postoperative outcome must be recognized, exceptions to current guidelines are justified under specific circumstances.

REFERENCES

1. AASLD COVID Working Group. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. 2021. Available at https://www.aasld.org/about-aasld/covid-19-and-liver. Accessed April 1, 2021.

2. Choi Y, Lee MK. Neuroimaging findings of brain MRI and CT in patients with COVID-19: a systematic review and meta-analysis. Eur J Radiol. 2020;133:109393.
3. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) guidelines. National Institutes of Health. 2021. Available at https://www.covid19treatmentguidelines.nih.gov. Accessed March 21, 2021.

4. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020;141:1903–1914.

5. Kruse JM, Magomedov A, Kurreck A, et al. Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care. 2020;24:676.

6. Kulkarni AV, Parthasarathy K, Kumar P, et al. Early liver transplantation after COVID-19 infection: the first report. Am J Transplant. 2021;21:2279–2284.

7. Rouphael G, D’Amico G, Ricci K, et al. Successful orthotopic liver transplantation in a patient with a positive SARS-CoV-2 test and acute liver failure secondary to acetaminophen overdose. Am J Transplant. 2021;21:1312–1316.

8. Yohanathan L, Corsini Campioli C, Mousa OY, et al. Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient. Am J Transplant. 2021;21:2890–2894.

9. Aquino-Jarquin G. The raw cycle threshold values from reverse-transcription polymerase chain reaction detection are not viral load quantitation units. Clin Infect Dis. 2021;72:1489–1490.

10. Fajnzylber J, Regan J, Coxen K, et al; Massachusetts Consortium for Pathogen Readiness. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11:5493.

11. Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73:807–816.

12. Rhee C, Kanjital S, Baker M, et al. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? Clin Infect Dis. 2021;72:1467–1474.

13. Choudhuri J, Carter J, Nelson R, et al. SARS-CoV-2 PCR cycle threshold value. J Clin Virol. 2020;129:104347.

14. Lagana SM, Kudose S, Iuga AC, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol. 2020;33:2147–2155.

15. Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73:807–816.

16. Phripps MM, Barraza LH, LaSota ED, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large U.S. cohort. Hepatology. 2020;72:807–817.

17. Wender P, Epstein M, Bernstein D. COVID-19 presenting as acute hepatitis. Am J Gastroenterol. 2020;115:941–942.

18. Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID-19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020;40:2110–2116.

19. Melquist S, Estepp K, Aleksandrovich Y, et al. COVID-19 presenting as fulminant hepatic failure: a case report. Medicine (Baltimore). 2020;99:e22818.

20. Belli LS, Fondevila C, Cortesi PA, et al; ELITA-ELTR COVID-19 Registry. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European Study. Gastroenterology. 2021;161:1151–1163.e3.

21. Colmenero J, Rodriguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74:148–155.

22. Webb GJ, Marje T, Cook JA, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020;5:1008–1016.

23. Nepogodiev D, Bhangu A, Glasbey JC, et al. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396:27–38.

24. Hochberg AB, Harrison EM, Green CA, et al; ISARIC4C investigators. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.

25. Bermejo-Martin JF, Gonzalez-Rivera M, Almansa R, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care. 2020;24:691.

26. Rao SN, Manissero D, Steele VR, et al. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020;9:573–586.

27. Tom MR, Mina MJ. To interpret the SARS-CoV-2 test, consider the cycle threshold value. Clin Infect Dis. 2020;71:2252–2254.

28. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. J Hepatol. 2020;72:807–816.

29. Gilead. Veklury (remdesivir): highlights of prescribing information. Available at https://www.gilead.com/-/media/files/medicines/covid-19/veklury/veklury_pi.pdf. Accessed March 2021.

30. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–574.

31. Gilead. Veklury (remdesivir): highlights of prescribing information. Available at https://www.gilead.com/-/media/files/medicines/covid-19/veklury/veklury_pi.pdf. Accessed March 2021.

32. D’Amico G, Ricci K, et al; Massachusetts Consortium for Pathogen Readiness. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11:5493.